BR112019007433A2 - sistemas de replicon de vírus recombinante e usos dos mesmos - Google Patents

sistemas de replicon de vírus recombinante e usos dos mesmos

Info

Publication number
BR112019007433A2
BR112019007433A2 BR112019007433A BR112019007433A BR112019007433A2 BR 112019007433 A2 BR112019007433 A2 BR 112019007433A2 BR 112019007433 A BR112019007433 A BR 112019007433A BR 112019007433 A BR112019007433 A BR 112019007433A BR 112019007433 A2 BR112019007433 A2 BR 112019007433A2
Authority
BR
Brazil
Prior art keywords
recombinant virus
interest
disclosure relates
virus replicon
replicon systems
Prior art date
Application number
BR112019007433A
Other languages
English (en)
Inventor
Iver Kamrud Kurt
Original Assignee
Synthetic Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Genomics Inc filed Critical Synthetic Genomics Inc
Publication of BR112019007433A2 publication Critical patent/BR112019007433A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente divulgação refere-se de forma geral a sistemas de expressão com base em vírus adequados para a produção de moléculas de interesse. a divulgação refere-se a construções de ácido nucleico, tais como vetores de expressão, que contêm um replicon de rna modificado que inclui uma região não traduzida a 5? (5?-utr) modificada e, opcionalmente, pelo menos parte de sua sequência viral original que codifica proteínas estruturais que foram deletadas. também são divulgados métodos para produção de polipeptídeos de interesse.
BR112019007433A 2016-10-17 2017-10-03 sistemas de replicon de vírus recombinante e usos dos mesmos BR112019007433A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662409228P 2016-10-17 2016-10-17
PCT/US2017/054928 WO2018075235A1 (en) 2016-10-17 2017-10-03 Recombinant virus replicon systems and uses thereof

Publications (1)

Publication Number Publication Date
BR112019007433A2 true BR112019007433A2 (pt) 2019-07-02

Family

ID=60153459

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007433A BR112019007433A2 (pt) 2016-10-17 2017-10-03 sistemas de replicon de vírus recombinante e usos dos mesmos

Country Status (10)

Country Link
US (2) US11364310B2 (pt)
EP (1) EP3526332B1 (pt)
JP (2) JP7382230B2 (pt)
KR (1) KR20190082226A (pt)
CN (1) CN110073002B (pt)
AU (1) AU2017347725B2 (pt)
BR (1) BR112019007433A2 (pt)
CA (1) CA3040264A1 (pt)
MX (1) MX2019004499A (pt)
WO (1) WO2018075235A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
CN110073002B (zh) 2016-10-17 2024-06-11 杨森制药公司 重组病毒复制子体系及其用途
KR102655641B1 (ko) 2016-12-05 2024-04-05 얀센 파마슈티칼즈, 인코포레이티드 유전자 발현을 향상시키기 위한 조성물 및 방법
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EP3740245A4 (en) 2018-01-19 2022-01-05 Janssen Pharmaceuticals, Inc. INDUCTION AND ENHANCEMENT OF IMMUNE RESPONSES USING RECOMBINATION REPLICON SYSTEMS
KR20200144093A (ko) 2018-02-17 2020-12-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 막 단백질 전달을 위한 조성물 및 방법
US20200109178A1 (en) * 2018-10-08 2020-04-09 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
US20220313815A1 (en) 2019-06-20 2022-10-06 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
CN116134131A (zh) 2019-12-31 2023-05-16 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
CN115484990A (zh) 2020-03-12 2022-12-16 基础科学研究院 诱导具有基因组序列变异的细胞凋亡的组合物及使用组合物诱导细胞凋亡的方法
GB2605538B (en) 2020-03-23 2024-06-26 Hdt Bio Corp Compositions and methods for delivery of RNA
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
CN115884786A (zh) 2020-05-11 2023-03-31 杨森制药公司 SARS-CoV-2疫苗
CN116096409A (zh) 2020-05-11 2023-05-09 杨森制药公司 编码稳定化的冠状病毒刺突蛋白的rna复制子
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
JP2023533528A (ja) 2020-07-08 2023-08-03 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖに対するｒｎａレプリコンワクチン
CN112458064A (zh) * 2020-11-20 2021-03-09 广西大学 盖他病毒全长感染性克隆、复制子***及其制备和应用
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
WO2023283641A1 (en) * 2021-07-09 2023-01-12 Replicate Bioscience, Inc. Modified eastern equine encephalitis viruses, self-replicating rna constructs, and uses thereof
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024008192A2 (zh) * 2022-07-08 2024-01-11 嘉晨西海(杭州)生物技术有限公司 经修饰的自复制mRNA

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4738927A (en) 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
WO1985002862A1 (en) 1983-12-23 1985-07-04 Monash University PRODUCTION OF HUMAN INTERFERON-alpha
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
JPH04503301A (ja) 1988-12-01 1992-06-18 ザ　トラスティーズ　オブ　ザ　ユニバーシティ　オブ　ノース　カロライナ 合成インターロイキン―６
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5246921A (en) 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
US5780036A (en) 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
CA2168583C (en) 1993-08-02 2007-10-02 Francis V. Chisari Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
DE19712889A1 (de) 1997-03-27 1998-10-01 Bosch Gmbh Robert Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
EA002087B1 (ru) 1997-04-03 2001-12-24 Электрофект Ас Способ введения фармацевтических препаратов и нуклеиновых кислот в скелетную мышцу
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
WO1999001158A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
US5958060A (en) 1998-01-02 1999-09-28 General Electric Company Method and apparatus for clock control and synchronization
AU770092B2 (en) 1998-07-13 2004-02-12 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
AU2001290642A1 (en) 2000-09-07 2002-03-22 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
US6538922B1 (en) 2000-09-27 2003-03-25 Sandisk Corporation Writable tracking cells
DE60116371T3 (de) 2000-11-23 2016-11-17 Bavarian Nordic A/S Variante des modifizierten vaccinia ankara virus
EP1363660A4 (en) 2001-02-01 2006-06-21 Univ Johns Hopkins HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
ATE354260T1 (de) 2001-07-19 2007-03-15 Ericsson Telefon Ab L M Verfahren und vorrichtung für die lösung der nummernübertragbarkeit am ursprungsort
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
WO2004055161A2 (en) 2002-12-12 2004-07-01 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
ATE432285T1 (de) 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US20050070700A1 (en) 2003-09-30 2005-03-31 Matthias Giese Equine arteritis virus vaccine
US9364664B2 (en) 2004-03-08 2016-06-14 Ichor Medical Systems, Inc. Apparatus for electrically mediated delivery of therapeutic agents
WO2007140522A1 (en) 2006-06-06 2007-12-13 Melbourne Health Detection and use of antiviral resistance mutations
WO2008115199A2 (en) * 2006-08-18 2008-09-25 The University Of North Carolina At Chapel Hill Chimeric virus vaccines
CN105457157B (zh) 2006-10-17 2020-04-14 因诺维奥制药公司 电穿孔装置及用其进行哺乳动物细胞电穿孔的方法
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
PL2183368T3 (pl) * 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
US20110110974A1 (en) 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
EP2461826A2 (en) 2009-08-07 2012-06-13 Transgene SA Composition for treating hbv infection
WO2011082388A2 (en) 2009-12-31 2011-07-07 Medigen, Inc . Infectious dna vaccines against chikungunya virus
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
DK2655621T3 (en) 2010-12-20 2018-08-13 Massachusetts Gen Hospital Polycomb-associated non-coding RNAS
MX343830B (es) 2011-02-11 2016-11-24 Univ Pennsylvania Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
JP2014524796A (ja) 2011-06-28 2014-09-25 イノビオ ファーマシューティカルズ，インコーポレイティド 低侵襲表皮電気穿孔装置
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
EP2932993B1 (en) 2012-12-13 2017-03-29 Panasonic Healthcare Holdings Co., Ltd. Medicament injection device
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
WO2016020538A1 (en) 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
KR20230145241A (ko) 2014-10-01 2023-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
CN107810009A (zh) 2015-05-15 2018-03-16 库瑞瓦格股份公司 涉及施用至少一种mRNA构建体的初免‑加强方案
CA2994694A1 (en) 2015-08-03 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
CA3018223A1 (en) 2016-03-28 2017-10-05 Ichor Medical Systems, Inc. Method and apparatus for delivery of therapeutic agents
CN118063563A (zh) 2016-04-06 2024-05-24 华盛顿大学 用于乙型肝炎病毒（hbv）的使用hbv核心抗原的治疗性疫苗
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
CN110073002B (zh) 2016-10-17 2024-06-11 杨森制药公司 重组病毒复制子体系及其用途
KR102655641B1 (ko) 2016-12-05 2024-04-05 얀센 파마슈티칼즈, 인코포레이티드 유전자 발현을 향상시키기 위한 조성물 및 방법
JP6613399B2 (ja) 2017-06-05 2019-12-04 株式会社ビークル Ｈｂｖに対する免疫応答を生じさせるために用いられるウイルス様粒子
CN111542340B (zh) 2017-11-16 2023-12-19 华盛顿大学 治疗性乙型肝炎病毒(hbv)疫苗
AU2018389787A1 (en) 2017-12-19 2020-06-25 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof

Also Published As

Publication number Publication date
KR20190082226A (ko) 2019-07-09
AU2017347725A1 (en) 2019-05-09
CA3040264A1 (en) 2018-04-26
AU2017347725B2 (en) 2024-01-04
US20230126773A1 (en) 2023-04-27
WO2018075235A1 (en) 2018-04-26
US20180104359A1 (en) 2018-04-19
CN110073002A (zh) 2019-07-30
JP7382230B2 (ja) 2023-11-16
EP3526332B1 (en) 2024-06-26
US11364310B2 (en) 2022-06-21
EP3526332A1 (en) 2019-08-21
MX2019004499A (es) 2019-11-18
CN110073002B (zh) 2024-06-11
JP2019530466A (ja) 2019-10-24
JP2023134488A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
CY1124689T1 (el) Trans-αντιγραφοymeno rna
BR112016007868A2 (pt) vacinas contra o vírus de epstein-barr
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
AU2018298422A1 (en) Novel nucleic acid molecules
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112018008051A2 (pt) vacinas de ácido nucleico para vírus de varicella zoster (vzv)
MX2018012376A (es) Sistemas de replicón de arterivirus recombinantes y usos de estos.
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
BR112019001115A2 (pt) proteínas de biofusão como vacinas anti-malária
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
WO2016130628A8 (en) Griffithsin mutants
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
BR112017001463A2 (pt) célula hospedeira melhorada para produzir proteínas
PE20170941A1 (es) Genes de tolerancia a herbicidas y metodos para usar los mismos
BR112018003580A2 (pt) molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante
BR112015019719A2 (pt) Proteínas melhoradas de ligação ao tnf
MX2019007924A (es) Vacunas contra la influenza.
BR112017024283A8 (pt) Vacinas contra a dengue

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]